Highlights Zhaoke Ophthalmology Limited

Equities

6622

KYG989M51017

Market Closed - Hong Kong S.E. Other stock markets 09:08:17 17/05/2024 BST			5-day change	1st Jan Change
1.59 ^HKD	+3.25%		+1.92%	-59.75%

04-29	Zhaoke Ophthalmology Shrinks Loss in 2023	MT
04-08	Zhaoke Ophthalmology Limited Announces the Resignation of Chen Yu Has as Non-Executive Director	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Zhaoke Ophthalmology Shrinks Loss in 2023	04-29	MT
Zhaoke Ophthalmology Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Zhaoke Ophthalmology Limited Announces Investigational New Drug Applications for Clinical Trial of Brimachol PF for the Treatment of Presbyopia	01-24	CI
Zhaoke Ophthalmology Limited Announces Positive Top-Line Results from NVK002 One-Year Phase III Clinical Trial (Mini-Champ) in China for the Treatment of Myopia Progress in Children and Adoption in China	12/10/23	CI
Zhaoke Ophthalmology Limited Provides Updates on Phase III Clinical Trials for Tab014 and Epinastine Hcl and Update on the New Drug Application for Cyclosporine A Ophthalmic Gel	03/10/23	CI
Zhaoke Ophthalmology's Loss Widens in H1	24/08/23	MT
Zhaoke Ophthalmology Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23/08/23	CI
Zhaoke Ophthalmology Limited Announces Completion of NVK002 Phase III Bridging Clinical Trial	09/08/23	CI
Zhaoke Ophthalmology Enters into Exclusive License, Supply and Distribution Agreement with Eyedetec Medical to Commercialize Eye Lipid Mobilizer for the Treatment of Dry Eye Disease	08/06/23	CI
Zhaoke Ophthalmology Loss Narrows in 2022	27/03/23	MT
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Commercialize Myopia Drug in South Korea	27/03/23	MT
Zhaoke Ophthalmology Limited Reports Earnings Results for the Full Year Ended December 31, 2022	27/03/23	CI
Zhaoke Ophthalmology Limited Enters into Distribution Agreement with Kwangdong Pharmaceutical to Commercialize NVK002 in South Korea	27/03/23	CI
Lee’s Pharmaceutical Holdings Warns of Plunge in 2022 Profit	21/03/23	MT
Zhaoke Ophthalmology Gets Nod for Marketing of Eye Drop	21/02/23	MT
Zhaoke Ophthalmology Limited Obtains Marketing Authorization for Bimatoprost Timolol Eye Drop from the National Medical Products Administration	20/02/23	CI
Zhaoke Ophthalmology's Ophthalmic Gel Passes Chinese Regulator's Clinical Trial Inspections	31/01/23	MT
Zhaoke Ophthalmology Limited Announces Cyclosporine A Ophthalmic Gel Passed the On-Site Regulatory and Clinical Trial Inspections	30/01/23	CI
Lee’s Pharmaceutical Q3 Profit Jumps 150%	17/11/22	MT
Zhaoke Ophthalmology Limited Reaches an Exclusive Distribution Agreement on Tono-I with C&V Tech	08/11/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Zhaoke Ophthalmology Limited

Equities

6622

KYG989M51017

Highlights

Filters